Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 7/20 | 0.70 |
| ▸ | PRKCA | P17252 | 4/20 | 0.64 |
| ▸ | CDK2 | P24941 | 2/20 | 0.59 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.59 |
| ▸ | CDK4 | P11802 | 1/20 | 0.59 |
| ▸ | CCND1 | P24385 | 1/20 | 0.59 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.59 |
| ▸ | KDR | P35968 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4985209 | 0.89 | GSK3B (0.56) | GSK3BPRKCACDK2CCNE2CDK4 | |
| SCHEMBL5257465 | 0.87 | GSK3B (0.75) | GSK3BPRKCAKDR | |
| SCHEMBL5256402 | 0.87 | GSK3B (0.65) | GSK3BPRKCACDK2CCNE2CDK4 | |
| SCHEMBL5255284 | 0.87 | GSK3B (0.77) | GSK3BPRKCAKDR | |
| SCHEMBL5257432 | 0.87 | GSK3B (0.77) | GSK3BPRKCAKDR | |
| SCHEMBL5257591 | 0.85 | GSK3B (0.63) | GSK3BPRKCACDK2CCNE2CDK4 | |
| SCHEMBL5254901 | 0.85 | CDK2 (0.62) | GSK3BPRKCACDK2CCNE2CDK4 | |
| SCHEMBL4991182 | 0.85 | GSK3B (0.75) | GSK3BKDR | |
| SCHEMBL4992178 | 0.85 | GSK3B (0.75) | GSK3BPRKCACDK4CCND1KDR | |
| SCHEMBL5258462 | 0.85 | GSK3B (0.75) | GSK3BPRKCACDK2CCNE2CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7405305-B2 | Pyrrole-2, 5dione derivatives and their used as GSK-3 inhibitors | ELI LILLY AND COMPANY (US) | 2008-07-29 | — | — | US | disclosed |
| EP-1487822-B1 | PYRROLE-2,5-DIONE DERIVATIVES AND THEIR USE AS GSK-3 INHIBITORS | LILLY CO ELI (US) | 2007-08-01 | — | — | EP | disclosed |
| US-20050288321-A1 | Kinase inhibitors | ELI LILLY AND COMPANY | 2005-12-29 | — | — | US | disclosed |
| CN-1639152-A | Pyrrole-2, 5-dione derivatives and their use as GSK-3 inhibitors | LILLY CO ELI (US) | 2005-07-13 | — | — | CN | disclosed |
| EP-1487822-A2 | PYRROLE-2,5-DIONE DERIVATIVES AND THEIR USE AS GSK-3 INHIBITORS | ELI LILLY AND COMPANY (US) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003076398-A2 | PYRROLE-2, 5-DIONE DERIVATIVES AND THEIR USE AS GSK-3 INHIBITORS | ELI LILLY AND COMPANY (US) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288321-A1 | Kinase inhibitors | ABL1, MAP3K20, MAP3K19 | GSK3B 205/4885PRKCA 44/4885CDK2 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.